Drug Trial Radar · NCT00403104
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 20, 2026Latest source record: Jun 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Nov 2006
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 23, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if oral treatment with ONO-2506PO in patients diagnosed with ALS, who have had onset of muscle weakness within 14 months of randomization, could lead to the slowing of decline in respiratory function, functional status, muscle strength, quality of life and survival compared with placebo group.
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
ONO-2506PODrug
1200 mg QD / 18 months
ONO-2506PODrug
0 mg QD / 18 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of decline of respiratory function determined as SVC over the 12 month treatment periodTime frame: 12 months
Locations
26 sites in 8 countries. Site status is shown where the registry gives one.
L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien
Vienna, Austria
UCL Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Hopital Roger Salengro - Clinique Neurologique, Neurologie A
Lille, France
Hopital Duruytren
Limoges, France
Hopital de la Timone
Marseille, France
Hopital de Chauliac
Montpellier, France
Hopital l-Archet 1
Nice, France
Hopital LaPitie Salpetriere
Paris, France
Charite Campus Virchow, ALS Ambulanz
Berlin, Germany
Neurologische Universitatsklinik Bergmannsheil
Bochum, Germany
Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik
Erlangen, Germany
Martin-Luther-Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie
Halle, Germany
Medizinische Hochschule Hannover, Neurologische Klinik
Hanover, Germany
Interdisziplinares Zentrum fur Palliativmedizin
München, Germany
Klinik und Poliklinik fur Neurologie der Universitat Ulm-Universitatsklinikum Ulm
Ulm, Germany
Deutsche Klinik fur Diagnostik, Fachbereich Neurologie
Wiesbaden, Germany
Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano
Milan, Italy
Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS
Pavia, Italy
Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette
Torino, Italy
Academic Medical Centre (AMC) Amsterdam - Dept of Neurology
Amsterdam, Netherlands
University Medial Center Utrecht
Utrecht, Netherlands
Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic
Sankt Gallen, Switzerland
Academic Neuroscience Centre
London, United Kingdom
Royal Preston Hospital
Preston, United Kingdom
University of Sheffield - Academic Neurology Unit
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.